Dew, I want CBAI to be a foaming at the mouth Eagle with Froth all over its' wings as it circles the globe gobbling up the weak blood companies it can.
We could make a deal that would cause capital restructuring without harming the investors, couldn't we?
Dew, here is a piece of the China puzzle blownup from an earlier post #34913. The Golden Meditech, Stem Cell Holdings Ltd, CordLife Ltd and CBAI.OB China play of the day has to be updated.
Add to it ThermoGenesis & Fenwal: Distribution agreement: ThermoGenesis & Fenwal ThermoGenesis, CA, USA (www.thermogenesis.com), has signed a new distribution agreement with Fenwal, Inc., IL, USA (www.fenwalinc.com).
((Look at what our China deal gets from ThermoGenesis and Fenwal))
Under the exclusive 5-year agreement, Fenwal will market and distribute the ThermoGenesis AXP™ AutoXpress™ System and BioArchive® System for use in cord blood processing and storage in China, India and Japan. Fenwal is a global provider of manual and automated products for blood collection, separation and storage, specializing in the development and sale of medical technology and single-use, sterile medical products, and serves blood and plasma centers and hospitals on five continents.
In August 2009, Fenwal and Golden Meditech of Hong Kong (www.goldenmeditech.com) agreed to form a joint venture in China to focus on blood collection and transfusion products.
Golden Meditech owns and operates a range of healthcare businesses in Asia. It has a majority stake in China Cord Blood Corporation (www.chinacordbloodcorp.com), the largest cord blood bank operator in China, and is the single largest shareholder of Cordlife Ltd. from Singapore (www.cordlife.com), the largest cord blood bank operator in southeast Asia.
News 
Market Data 
Discover 
